This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IMRIS Launches VISIUS Surgical Theatre(TM)

-- Converged product positioning reflects breadth and utility of clinical applications --

WINNIPEG, Oct. 3, 2011 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS) (TSX: IM) ("IMRIS" or the "Company") today officially launched VISIUS Surgical Theatre TM , its new global product branding at the Congress of Neurological Surgeons (CNS) being held in Washington DC. Under the new strategy, the Company's image guided therapy suites will be singly branded the VISIUS Surgical Theatre to communicate the scope and flexibility of IMRIS's image guided therapy suites across a range of clinical applications.

"The decision to converge the company's individual product names - IMRISneuro, IMRIScardio and IMRISNV - reflects the evolution of our technology and our vision" said IMRIS CEO, David Graves.  " VISIUS Surgical Theatre communicates the value we deliver to our customers seeking better clinical vision, enhanced precision in treatment and optimal room utilization. By choosing the VISIUS Surgical Theatre, our customers will be able to drive utility by not having to choose just one application."

The VISIUS Surgical Theatre is a revolutionary, multifunctional surgical environment that delivers unmatched intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Designed to meet each hospital's specific clinical application needs, the VISIUS Surgical Theatre can incorporate MR imaging, CT imaging and x-ray angiography in a number of configurations to provide intraoperative images of diagnostic quality - without introducing additional risk to the patient associated with patient transport - delivering real-time information to clinicians while preserving optimal surgical access and techniques.

When a VISIUS Surgical Theatre is equipped with a ceiling-mounted MR scanner and an integrated x-ray angiography system, it becomes the only Hybrid-OR in the world, in which patients can be scanned in the MR, treated on the angio system, and scanned again in the MR to verify treatment - without ever leaving the operating room table. The breadth of open surgical applications and catheter-based treatments in this environment creates opportunities for multiple departments to collaborate on its investment and to optimize its utilization. With the ability to improve vision, enhance precision and improve patient outcomes in neurosurgery and guided interventional procedures in cardiovascular and cerebrovascular applications, the VISIUS Surgical Theatre is the complete Image Guided Therapy Solution.

In conjunction with today's launch, IMRIS will be exhibiting several exciting new products at CNS that further enhance the capabilities and utility of the VISIUS Surgical Theatre including the ORT200 Removable Operating Room Table, Stereotactic Adaptor, AccuTrack anatomical navigation system 1 and an intraoperative CT system. A demonstration of IMRIS's image guided surgical robotic technology will also be featured at CNS. Garnette Sutherland, MD, Professor of Neurosurgery at University of Calgary Foothills Hospital will present to visitors in the IMRIS booth, sharing his experience in image-guided surgical robotics.

Further information on the VISIUS Surgical Theatre is available on the Company's new website which is also being unveiled today as part of the branding strategy.


IMRIS (NASDAQ: IMRS) (TSX: IM) is a global leader in providing image guided therapy solutions through its VISIUS Surgical Theatre - a revolutionary, multifunctional surgical environment that provides unmatched intraoperative vision to clinicians to assist in decision making and enhance precision in treatment. VISIUS Surgical Theatres serve the neurosurgical, cardiovascular and cerebrovascular markets and have been selected by leading medical institutions around the world.

Images:  Press quality images are available at the IMRIS site:

1 AccuTrack has Health Canada clearance and CE Mark regulatory clearance in Europe.  AccuTrack is not available for sale in the U.S.


1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.64 -0.11%
FB $118.57 0.84%
GOOG $698.21 0.75%
TSLA $241.80 0.43%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs